A groundbreaking deal between the government and pharmaceutical companies will allow thousands of women in England with incurable HER2-low advanced breast cancer to access the life-extending drug Enhertu through the NHS starting this week. The agreement follows successful negotiations over pricing, ensuring the treatment becomes available for around 1,000 patients annually. Enhertu has shown potential to prolong survival for those with this specific type of aggressive cancer, offering new hope for a patient group previously limited in treatment options. The move marks a significant step forward in expanding access to cutting-edge therapies for serious illnesses within the public healthcare system.
Thousands with HER2-low advanced breast cancer will have access to Enhertu after ministers strike deal on priceThousands of women in England with incurable breast cancer will get access to a life-extending drug on the NHS after negotiations over its cost proved successful.About 1,000 women a year with HER2-low advanced breast cancer will be able to obtain Enhertu from Thursday after ministers and the drug’s makers struck a deal on its price. Continue reading...
